IFNG and cancer: Although the failure to achieve desirable clinical outcomes with early immunotherapies such as interferon-gamma (IFN-γ) and interleukin (IL)-2 treatments, novel immunotherapies launched in the 21st century have achieved robust clinical results, establishing cancer immunotherapy as one of the foremost anchors of anticancer therapies (Lesterhuis et al., 2011; Jiang T. et al., 2016; Castro et al., 2018).